AUROPHARMA.NS Profit & Loss
Aurobindo Pharma Ltd.
Profit & Loss Balance Sheet Cash Flow
Profit & Loss · 4 years on file
(FY2022-23 to FY2025-26)
· fetched 2026-08-23 21:36
| Line item | FY2022-23 | FY2023-24 | FY2024-25 | FY2025-26 | Source (XBRL element) |
|---|---|---|---|---|---|
| Revenue from Operations | ₹24,855.38 Cr. | ₹29,001.87 Cr. | ₹31,723.73 Cr. | ₹33,653.08 Cr. | RevenueFromOperations |
| Gross Revenue (incl. inter-segment) | N/A | N/A | N/A | N/A | SegmentRevenueFromOperations |
| Other Income | ₹290.59 Cr. | ₹557.38 Cr. | ₹621.85 Cr. | ₹492.09 Cr. | OtherIncome |
| Total Income | ₹25,145.97 Cr. | ₹29,559.25 Cr. | ₹32,345.58 Cr. | ₹34,145.17 Cr. | Income |
| Cost of Materials Consumed | ₹9,652.51 Cr. | ₹10,776.14 Cr. | ₹10,736.76 Cr. | ₹10,305.19 Cr. | CostOfMaterialsConsumed |
| Purchases of Stock-in-Trade | ₹2,050.43 Cr. | ₹2,772.93 Cr. | ₹2,887.11 Cr. | ₹3,477.98 Cr. | PurchasesOfStockInTrade |
| Changes in Inventories | ₹-409.68 Cr. | ₹-946.17 Cr. | ₹-597.63 Cr. | ₹-294.81 Cr. | ChangesInInventoriesOfFinishedGoodsWorkInProgressAndStockInTrade |
| Employee Benefit Expense | ₹3,522.25 Cr. | ₹3,922.94 Cr. | ₹4,475.62 Cr. | ₹5,190.17 Cr. | EmployeeBenefitExpense |
| Finance Costs | ₹140.48 Cr. | ₹289.71 Cr. | ₹457.24 Cr. | ₹383.97 Cr. | FinanceCosts |
| Depreciation and Amortisation | ₹1,244.58 Cr. | ₹1,521.66 Cr. | ₹1,649.42 Cr. | ₹1,778.19 Cr. | DepreciationDepletionAndAmortisationExpense |
| Other Expenses | ₹6,321.23 Cr. | ₹6,633.03 Cr. | ₹7,639.08 Cr. | ₹8,128.82 Cr. | OtherExpenses |
| Total Expenses | ₹22,521.80 Cr. | ₹24,970.24 Cr. | ₹27,247.60 Cr. | ₹28,969.51 Cr. | Expenses |
| Profit Before Exceptional Items and Tax | ₹2,624.17 Cr. | ₹4,589.01 Cr. | ₹5,097.98 Cr. | ₹5,175.66 Cr. | ProfitBeforeExceptionalItemsAndTax |
| Exceptional Items | ₹0.00 Cr. | ₹-191.86 Cr. | ₹0.00 Cr. | ₹-65.33 Cr. | ExceptionalItemsBeforeTax |
| Profit Before Tax | ₹2,624.17 Cr. | ₹4,397.15 Cr. | ₹5,097.98 Cr. | ₹5,110.33 Cr. | ProfitBeforeTax |
| Tax Expense | ₹684.85 Cr. | ₹1,211.02 Cr. | ₹1,582.72 Cr. | ₹1,608.88 Cr. | TaxExpense |
| Net Profit (incl. minority interest) | ₹1,927.65 Cr. | ₹3,168.97 Cr. | ₹3,483.57 Cr. | ₹3,502.97 Cr. | ProfitLossForPeriod |
| Net Profit (to shareholders) | ₹1,927.50 Cr. | ₹3,172.97 Cr. | ₹3,485.88 Cr. | ₹3,504.75 Cr. | ProfitOrLossAttributableToOwnersOfParent |
| Basic EPS | ₹32.90 | ₹54.16 | ₹59.81 | ₹60.34 | BasicEarningsLossPerShareFromContinuingAndDiscontinuedOperations |
| Diluted EPS | ₹32.90 | ₹54.16 | ₹59.81 | ₹60.34 | DilutedEarningsLossPerShareFromContinuingAndDiscontinuedOperations |
Every figure above is the exact value of the named XBRL element from AUROPHARMA.NS's cached filing for that year — nothing here is estimated or backfilled. A company shows one column per year StockProof actually has data for — never padded with blank years. Rows shown as N/A are genuinely not disclosed under that year's filing format (see peer comparison for how other Healthcare companies compare).